BioPortfolio Provides:

  • comprehensive market data
  • up to date reports
  • personal "find a report" service
  • reliable and quick

Contact us with your report needs NOW!

+44 1300 321501
priority@bioportfolio.com

BioPortfolio Specialist Market Reports:
Biotechnology, Life Science
Healthcare and Pharmaceutical
Market Research and Corporate Data

Search our store now...

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2013

Published Jun 29, 2013 - 49 pages - Format: PDF - SKU: GMDHC3738IDB

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).
- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 7
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics under Development by Companies 9
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Products under Development by Companies 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Development 16
AstraZeneca PLC 16
Eli Lilly and Company 17
La Jolla Pharmaceutical Company 18
Hawthorn Pharmaceuticals, Inc. 19
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
tabalumab - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
atorvastatin calcium - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GCS-100 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Haw Nuv-15 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Haw Nuv-16 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AZD-1722 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LJPC-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Recombinant Cystathionine Beta Synthase - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Drug Profile Updates 36
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Discontinued Products 41
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Dormant Products 42
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Product Development Milestones 43
Featured News & Press Releases 43
Jun 03, 2013: Keryx Biopharma Announces Presentation Of Zerenex Phase III Data At 2013 World Congress Of Nephrology 43
May 06, 2013: Trevi Therapeutics Commences Phase I Clinical Study Of Nalbuphine ER In End-Stage Renal Disease Patients On Hemodialysis 44
Apr 04, 2013: Shire Regenerative Medicine Initiates Two Phase II Studies Evaluating Vascugel In Patients With End-Stage Renal Disease Undergoing Arteriovenous Access Creation For Hemodialysis 44
Aug 28, 2012: Rockwell Medical Receives Canadian Patent For SFP Formulation For Iron-Delivery In Hemodialysis Patients 45
Jul 31, 2012: Rockwell Medical Completes Patient Enrollment In Phase III Clinical Trials For SFP Iron-Delivery In Hemodialysis Patients 45
Jul 31, 2012: La Jolla Pharma Announces FDA Agreement With Proposed Phase I Clinical Trial Of GCS-100 In Chronic Kidney Disease 46
Jun 27, 2012: Rockwell Medical Receives Canadian Patent For SFP-Iron Delivery 46
Apr 30, 2012: Rockwell Medical Completes Patient Enrollment In PRIME Clinical Study 46
Mar 19, 2012: Rockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies To Continue as Planned 47
Dec 12, 2011: Rockwell Medical Data Safety Monitoring Board Recommends Phase III CRUISE Studies Continue As Planned 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2013 7
Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24
List of Tables
Number of Products Under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2013 7
Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
AstraZeneca PLC, H1 2013 16
Eli Lilly and Company, H1 2013 17
La Jolla Pharmaceutical Company, H1 2013 18
Hawthorn Pharmaceuticals, Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Drug Profile Updates 36
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Discontinued Products 41
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics – Dormant Products 42

Publisher: Global Markets Direct

Format: PDF

Pages: 49

Publisher Reference: GMDHC3738IDB

Date Published: 2013-06-29

Date Added: 2013-07-12 06:24:11

Purchasing
Select the report required - click the green button and follow the online instructions

Payment
BioPortfolio operates a secure e-commerce facility in partnership with Worldpay. Alternatively, pro-forma payment can be made by bank transfer.

Delivery Details
BioPortfolio manages the dispatch of report orders following payment - we use our best endeavors to get PDF files to our customers within the hour.

User License
Reports are sold under license:

  • Single User - The report can only be used by the purchaser.
  • Site - The report can be shared between users at a single site/location.
  • Global/Enterprise - The user is free to distribute the report across their entire organization.

Publisher Info

Global Markets Direct are a leading provider of global business intelligence and market analysis. GMD publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

Topic Context

Global

Global means of or referring to a globe and may also refer to: [more]

Ordering

Buy with Credit Card or Pro Forma Invoice

Easy Payment Options

We accept the following credit cards...
Visa Credit payments supported by WorldPayVisa Debit payments supported by WorldPayMastercard payments supported by WorldPayAmerican Express payments supported by WorldPayWorldPay Payments Processing

Or we can raise a pro forma invoice if you prefer.

Buy With Confidence

BioPortfolio has been selling market reports for over 16 years from the world's leading market research companies.

Personal Service

Our team will work with you to source the best report for your needs. We can liaise with publishers to obtain sample pages and negotiate discounts where available.

Market Leader

With over 15,000 visitors to our websites every day, BioPortfolio is the world's leading biotech, healthcare and medical resource online.